Co-creation using crowdsourcing to promote PrEP adherence in China: study protocol for a stepped-wedge randomized controlled trial.
Adherence
China
Co-creation
GBMSM
PrEP
Randomized controlled trial
Stepped-wedge design
Transgender
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
07 09 2022
07 09 2022
Historique:
received:
16
10
2021
accepted:
02
09
2022
entrez:
7
9
2022
pubmed:
8
9
2022
medline:
11
9
2022
Statut:
epublish
Résumé
Adherent pre-exposure prophylaxis (PrEP) uptake can prevent HIV infections. Despite the high HIV incidence, Chinese key populations have low PrEP uptake and adherence. New interventions are needed to increase PrEP adherence among key populations in China. Co-creation methods are helpful to solicit ideas from the community to solve public health problems. The study protocol aims to describe the design of a stepped-wedge trial and to evaluate the efficacy of co-created interventions to facilitate PrEP adherence among key populations in China. The study will develop intervention packages to facilitate PrEP adherence among Chinese key populations using co-creation methods. The study will then evaluate the efficacy of the co-created intervention packages using a stepped-wedge randomized controlled trial. This four-phased closed cohort stepped-wedge design will have four clusters. Each cluster will start intervention at three-month intervals. Seven hundred participants who initiated PrEP will be recruited. Participants will be randomized to the clusters using block randomization. The intervention condition includes receiving co-created interventions in addition to standard of care. The control condition is the standard of care that includes routine clinical assessment every 3 months. All participants will also receive an online follow-up survey every 3 months to record medication adherence and will be encouraged to use a WeChat mini-app for sexual and mental health education throughout the study. The primary outcomes are PrEP adherence and retention in PrEP care throughout the study period. We will examine a hypothesis that a co-created intervention can facilitate PrEP adherence. Generalized linear mixed models will be used for the primary outcome analysis. Developing PrEP adherence interventions in China faces barriers including suboptimal PrEP uptake among key populations, the lack of effective PrEP service delivery models, and insufficient community engagement in PrEP initiatives. Our study design addresses these obstacles by using co-creation to generate social media-based intervention materials and embedding the study design in the local healthcare system. The study outcomes may have implications for policy and intervention practices among CBOs and the medical system to facilitate PrEP adherence among key populations. The study is registered in Clinical Trial databases in China (ChiCTR2100048981, July 19, 2021) and the US (NCT04754139, February 11, 2021).
Sections du résumé
BACKGROUND
Adherent pre-exposure prophylaxis (PrEP) uptake can prevent HIV infections. Despite the high HIV incidence, Chinese key populations have low PrEP uptake and adherence. New interventions are needed to increase PrEP adherence among key populations in China. Co-creation methods are helpful to solicit ideas from the community to solve public health problems. The study protocol aims to describe the design of a stepped-wedge trial and to evaluate the efficacy of co-created interventions to facilitate PrEP adherence among key populations in China.
METHODS
The study will develop intervention packages to facilitate PrEP adherence among Chinese key populations using co-creation methods. The study will then evaluate the efficacy of the co-created intervention packages using a stepped-wedge randomized controlled trial. This four-phased closed cohort stepped-wedge design will have four clusters. Each cluster will start intervention at three-month intervals. Seven hundred participants who initiated PrEP will be recruited. Participants will be randomized to the clusters using block randomization. The intervention condition includes receiving co-created interventions in addition to standard of care. The control condition is the standard of care that includes routine clinical assessment every 3 months. All participants will also receive an online follow-up survey every 3 months to record medication adherence and will be encouraged to use a WeChat mini-app for sexual and mental health education throughout the study. The primary outcomes are PrEP adherence and retention in PrEP care throughout the study period. We will examine a hypothesis that a co-created intervention can facilitate PrEP adherence. Generalized linear mixed models will be used for the primary outcome analysis.
DISCUSSION
Developing PrEP adherence interventions in China faces barriers including suboptimal PrEP uptake among key populations, the lack of effective PrEP service delivery models, and insufficient community engagement in PrEP initiatives. Our study design addresses these obstacles by using co-creation to generate social media-based intervention materials and embedding the study design in the local healthcare system. The study outcomes may have implications for policy and intervention practices among CBOs and the medical system to facilitate PrEP adherence among key populations.
TRIAL REGISTRATION
The study is registered in Clinical Trial databases in China (ChiCTR2100048981, July 19, 2021) and the US (NCT04754139, February 11, 2021).
Identifiants
pubmed: 36071401
doi: 10.1186/s12889-022-14117-5
pii: 10.1186/s12889-022-14117-5
pmc: PMC9449927
doi:
Banques de données
ClinicalTrials.gov
['NCT04754139']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1697Informations de copyright
© 2022. The Author(s).
Références
PeerJ. 2019 Apr 12;7:e6762
pubmed: 30997295
Lancet HIV. 2020 Mar;7(3):e155-e157
pubmed: 31473165
Stat Methods Med Res. 2021 Feb;30(2):612-639
pubmed: 32631142
BMC Infect Dis. 2020 Apr 22;20(1):299
pubmed: 32321442
Lancet HIV. 2017 Sep;4(9):e402-e410
pubmed: 28747274
AIDS Behav. 2015 May;19(5):794-801
pubmed: 25432877
J Med Internet Res. 2018 May 15;20(5):e187
pubmed: 29764795
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
Mhealth. 2021 Apr 20;7:38
pubmed: 33898607
BMJ. 2020 Apr 2;369:m1043
pubmed: 32241761
Trials. 2015 Aug 17;16:350
pubmed: 26279013
Trials. 2017 Mar 9;18(1):119
pubmed: 28279222
BMC Infect Dis. 2019 Nov 27;19(1):1000
pubmed: 31775654
Infect Dis Poverty. 2020 Jan 20;9(1):8
pubmed: 31959234
Trials. 2009 Jun 03;10:37
pubmed: 19493350
AIDS Behav. 2021 Mar;25(3):866-874
pubmed: 32989576
Trials. 2020 Nov 17;21(1):931
pubmed: 33203449
Curr Opin HIV AIDS. 2016 Jan;11(1):10-7
pubmed: 26633638
BMJ Open. 2022 May 10;12(5):e055899
pubmed: 35537794
Contemp Clin Trials. 2007 Feb;28(2):182-91
pubmed: 16829207
Trials. 2015 Aug 16;16:359
pubmed: 26275907
PLoS Med. 2018 Aug 28;15(8):e1002645
pubmed: 30153265
Curr HIV/AIDS Rep. 2019 Aug;16(4):270-278
pubmed: 31155691
Trials. 2017 Oct 2;18(1):447
pubmed: 28969702
Int J Infect Dis. 2018 Oct;75:52-59
pubmed: 30125688
Lancet HIV. 2021 Mar;8(3):e130-e137
pubmed: 33662265
Lancet HIV. 2021 Jul;8(7):e420-e428
pubmed: 34048794
Curr HIV/AIDS Rep. 2019 Dec;16(6):458-466
pubmed: 31773405
BMC Med Res Methodol. 2017 Sep 18;17(1):144
pubmed: 28923013
J Int AIDS Soc. 2020 Nov;23(11):e25636
pubmed: 33247553
J Int AIDS Soc. 2020 Sep;23 Suppl 5:e25564
pubmed: 32869511